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Chapter 1 Introduction and literature review 
Human Cytomegalovirus (HCMV) first entered the realm of medical literature 
in 1904 when it was described as a large cell with intranuclear inclusions 
bodies. Found in the viscera and salivary glands of infants with what was 
then considered congenital syphilis, these cells which had an "owl's eye" 
appearance were initially thought to be protozoan-like. It was not until 1956, 
when cell culture techniques became available that HCMV was isolated from 
various laboratories(15;43;46). To this day, congenital HCMV infection is the 
most common viral cause of mental retardation and remains a public health 
priority worldwide. 
HCMV is the fifth member of the family Herpesviridae. It belongs to the 
subfamily betaherpesvirinae and genus Cytomegalovirus. CMV shares the 
key characteristic of latent infection with its kin in the herpesviridae family, 
which allows CMV to persist in the host following infection. Like many other 
herpes viruses, primary CMV infection causes minimal disease in the 
infected host and is often subclinical. 
Through complex cascades of viral gene expression, CMV is able to regulate 
its replication, evade the immune system and reactivate from its latent 
reservoirs from time to time. This biological property of HCMV can be 
observed in the clinical setting as intermittent viral shedding in the bodily 
'Huids of infected but asymptomatic individuals. The persistent and insidious 
nature of CMV has important bearing on its epidemiology and transmission. 
Epidemiology and pathogenesis of CMV 
In non-industrialised countries where the standard of hygiene is poor, the 
prevalence of CMV infection is particularly high. Local seroprevalence data 
suggests more than 90% of adolescents in South Africa are infected with 
CMV(30). This in tum means that the majority of child bearing women may 
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shed CMV in the genital tract and beast milk. Swallowing of genital 
secretions and breast milk by the newborn during the perinatal period 
accounts for a large proportion of infection in this setting. In industrialised 
countries where the standard of hygiene is high, the adult seroprevalence of 
HCMV in the adult population is lower. Little more than half of pregnant 
women are infected with CMV(39). As a result, the common modes of 
transmission of CMV are between toddlers in creches and playschools(2). 
This creates an interesting scenario in which the need for research into CMV 
is very different for developed and developing countries. In developed 
countries, many pregnant females are not immune to CMV and are at risk of 
acquiring primary CMV infection during pregnancy. This is associated with 
high risk for symptomatic congenital infection for the foetus(18). Therefore 
much focus in paediatric CMV research in the first world has largely been on 
prevention and diagnosis of congenital CMV infection. However, the research 
needs in developing countries are entirely different. 
HCMV has a wide natural tissue tropism. This is evident as the virus can be 
cultured from secretions from various mucosal surfaces including saliva, 
urine, genital secretions and stool. During the time of reactivation, CMV 
inclusion bodies can be observed in the histological sections of various 
tissues, mostly glandular epithelium, endothelium, and white blood cells of 
myeloid lineage. Isolation of CMV from these sites does not necessarily 
indicate CMV end organ disease (EOD). Many tissues may be a reservoir of 
latent CMV infection from which CMV virions are produced on an ongoing or 
intermittent basis. The epithelial tissue of the salivary gland and kidney are 
the two main reservoirs of HCMV, but any cells capable of harbouring CMV 
may potentially be responsible for the persistence of the virus. 
Most of the medical literature on Cytomegalovirus reports CMV disease in 
two groups of susceptible individuals. Congenital infection or CMV infection 
affecting the pregnant women and the foetus or newborn had been well 
described historically. In the modern era of medicine, CMV has also emerged 
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as a significant pathogen in the immunocompromised population. With the 
advent of transplantation medicine and the use of sophisticated 
immunosuppressive agents, CMV has become a formidable infection in both 
bone marrow and solid organ transplant recipients. CMV EOD's are 
commonly observed in such immunocompromised patients. The disease 
spectrum includes retinitis, central nervous system disease, oesophagitis, 
colitis, pneumonitis, and disseminated disease(28). 
In Sub-Saharan Africa, the burden of disease is more commonly observed in 
another immunocompromised host, namely patients with advanced HIV 
infection. CMV end organ diseases in HIV infected adults, most commonly 
retinitis, CNS disease and gut disease, are AIDS defining illnesses that 
usually occur when the CD4 count is below 50 celis/J.d. In the era of Highly 
Active Anti-Retroviral Therapy (HAARn, CMV disease in HIV infected adults 
has largely been limited to those who have very limited access to HIV care. 
Although many patients seeking HIV care for the first time still present with 
very low CD4 counts, most CMV disease in sub-Saharan Africa is seen in 
HIV infected infants. 
According to the latest Joint United Nations Programme on HIV/AIDS 
(UNAIDS) data, approximately 420,000 newborns were infected by HIV 
worldwide in 2007. Two million HIV infected children, representing 85% of all 
HIV infected children, are living in sub-Saharan Africa. They represent an 
important group of CMV disease that contributes to the majority of CMV 
disease burden in South Africa. In HIV infected infants and children, CMV 
disease may follow congenital infection or subsequent postnatal exposure. 
Due to impaired cell-mediated immunity, these children are unable to control 
CMV replication and may display more aggressive manifestations of local or 
systemic CMV disease. A recent Gambian study (29) confirms that 
transmission occurs in the first three months of life in most African children. 
Where infants are co-infected with HIV and CMV, the children are often 
profoundly immunosuppressed. HIV/CMV co-infection results, not only in 
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CMV disease in the various organ systems, but it accelerates HIV disease 
progression and predisposes the child to further opportunistic 
infections(31 ;38). Dually infected infants frequently have co-morbidities and 
the diagnosis of CMV EOD can be difficult and often requires numerous 
invasive procedures and a multitude of time-consuming laboratory tests to 
identify the cause. 
Laboratory Tools for diagnosis of CMV 
Methods of CMV identification have been constantly evolving for the last 50 
years. The original viral culture method used to identify CMV is still very 
relevant today. Compared to the traditional culture of the past, modern CMV 
culture has been modified to reduce laboratory turnaround time. Instead of 
using a monolayer of human fibroblasts on a coverslip in sloped tube culture, 
specially adapted "Shell Vials" with round coverslips are used. Following 
inoculation of the clinical sample onto the human fibroblast containing Shell 
Vial, a centrifugation step is performed to disrupt the cell barrier and facilitate 
viral entry and infection of the cell monolayer. The culture is incubated at 
37°C for 48 hours and stained with a CMV specific monoclonal antibody to 
identify viral antigen, in most cases product of an immediate early gene of 
HCMV. The process is shorted to two days without losing much sensitivity. 
To diagnose CMV infection in congenitally infected neonates, CMV Shell Vial 
culture on urine is still considered the gold standard today(5). 
Serological assays detecting CMV IgG and IgM are also still widely used 
albeit in limited clinical contexts. Due to the indirect nature of antibody tests, 
serological assays for CMV have been restricted to checking immune status 
or detecting symptomatic primary infection in adults. CMV IgM is prone to 
false positive results. In addition, IgM assays may often be reactive during an 
episode of subclinical CMV reactivation, further limiting it use for predicting 
CMV disease. In developing countries where CMV infection and reactivation 
is common, CMV IgG and IgM have a very low positive predictive value for 
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primary CMV infection and CMV disease. In the paediatric setting where 
maternal antibody further complicates the issue, CMV Enzyme-Linked 
ImmunoSorbent Assays (ELISA's) play almost no role in diagnosis or 
management of CMV disease. 
Histology is one of the oldest methods available for diagnosing CMV disease, 
but is still considered to be the most specific test for CMV disease today (35) 
because it is the only assay that can visualise the effect of HCMV at the site 
of the end organ. The characteristic "Owl's eye" appearance (or Cowdry type 
A intra-nuclear inclusions) is well recognised by histopathologists. There are 
two problems with using histology as the primary tool for the diagnosis of 
CMV disease. The first problem is the requirement of an invasive procedure 
to retrieve tissue samples. Procedures such as biopsy can only be performed 
by skilled staff and in an adequately equipped healthcare facility. Secondly 
the sensitivity of histology is especially dependent on the appropriate area 
with CMV disease being sampled and examination of an adequate number of 
sections. In an ill infant, invasive procedure to reliably obtain tissue from the 
diseased area is often difficult. Examinati0n of multiple histological sections is 
time consuming and may be inefficient if the tissue sample is from a normal 
tissue. 
During the search for better marker of systemic CMV disease, 
polymorphonuclear leukocytes (PMN) from individuals with CMV disease 
were found to contain CMV antigens. Although the pathogenesis of this 
phenomenon has never been elucidated, the technique of CMV 
antigenaemia was pioneered and has been used in the laboratory for 
screening for CMV activity in post transplant patients for many years. The 
principle of the assay consists of isolation of PMN and staining with a 
monoclonal antibody directed against the lower matrix protein of CMV, 
namely antigen pp65. This is a semi-quantitative assay and the result is 
expressed as number of pp65 positive cells per number of cells used to 
prepare the slide (usually 200,000 white blood cells). CMV antigenaemia has 
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been used to identify CMV disease in HIV infected patient with some success 
but its use in young infants in less than 6 months has been found to lack 
sensitivity. CMVantigenaemia has a few disadvantages, namely, the assay 
is labour intensive and requires sufficient number of white cells. Despite its 
relatively short turnaround time (5 hours of laboratory processing), the labour 
intensive nature makes antigenaemia assay tricky to perform when there are 
a large number of samples. In neutropenia or very young infants, obtaining 
sufficient white cells for the assay is often difficult. Furthermore, the 
fluorescent microscopy is subjected to the skill and experience of the 
microscopist. 
Development of the Polymerase Chain Reaction (PCR) was one of the big 
breakthroughs in the field of molecular biology. PCR is able to amplify minute 
amounts of target nucleic acid and has since played an important role in 
diagnostic laboratories. In the field of CMV diagnostics, PCR is able to detect 
not only DNA from viable virus, but also viral DNA in body fluids or tissue 
where the infected cells have been lysed due to CMV replication. In many 
virology diagnostic laboratories around the world, the technology of PCR has 
made cell culture facility redundant. The exquisite sensitivity of PCR can 
often be a drawback as the presence of very low levels of viral DNA may not 
always be clinically significant. In recent years, further development of PCR 
has allowed the target to be quantified. 
With the aid of quantitative PCR, virologists have been able to move one step 
closer to understanding the pathogenesis of HCMV by monitoring the 
replication dynamics of CMV in individuals susceptible to CMV disease. 
Observations from various prospective immunocompromised cohorts have 
revealed two interesting findings. Firstly CMV viraemia, or more correctly 
CMV DNAemia (presence of CMV DNA in the blood), is the main predictor of 
CMV disease in many immunocpmpromised cohorts(9;13;20). Secondly, 
serial monitoring of CMV viral load has shown that most individuals have a 
tolerance for a certain level of viraemia before developing CMV EOD. As the 
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CMV vlfalload Increases the likelihood of developing EOn remains low 
ir'lltialiy but when the tolerance threshold IS exceeded, the probability of 
devetoping CMV disease Increases exponentially This threshold concept of 
CMV disease may be explained by the double tap and drain cartoon (Figure 
1) 




from latent Slles 
"'" ""1'1 medililed immunity 
End organ 
CMVdlsease 
Figure 1 Interactions between CMV productJon, cell mediated Immune 
response and CMVend organ disease. (Modified from Griffiths PD 
CytomegaloVIrUS In Zuckerman AJ, Banatvala JE et al eO PnnClples and 
Practices of Cluncal Vuu/ogy 5'" ed John Wiley & Sons Ltd 2004) 
The tap and small baSin represents nominal CMV replication, InSUffiClenllo 
result In disease, from the lalef1tJy Infected cell population ThiS replication IS 
kept !n check; by local cell mediated immune responses When the local 
conditIonS favour excessive CMV replication, the ViruS spills Into the systemiC 
CIrculation (represented by the larger baSin In the cartoon). The systemiC 
immune response also controls the level of viraemia When the host IS 
suffICIently Immunosuppressed, VIral replicahon spills Into [he end organs 
leading 10 disease The pathophysiology of CMV disease is likely to be muJtI~ 
faciorlal and beyond the scope ollhls dISsertation The literature suggests 
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that direct cell lysis, disruption of integrity of the epithelium/endothelium, 
and/or immunopathology all play an important role in causing EOD when the 
threshold of viral replication is exceeded (23). 
Real time quantitative PCR has been gaining popularity in pathology 
laboratories both locally and internationally. CMV viral load has made a quick 
transition from being a research tool to the gold standard assay in many 
virology laboratories. The technique combines the sensitivity of PCR and the 
specificity of fluorescent probes to provide a quantitative result with a 
relatively short turn around time. This makes real time PCR an attractive 
method for monitoring CMV activity in post transplant patients where rapid 
clinical decision-making and an early diagnosis is essential. Numerous 
studies examining the relationship between blood CMV DNA level and the 
risk of CMV disease showed a level of 5000-100,000 CMV DNA copies per 
ml of whole blood as the potential threshold for significant CMV disease(17). 
There is very little published data on the diagnosis of CMV disease in HIV 
infected children using real time PCR. Whether the data gathered from the 
adult post transplant setting can be translated to children, more specifically 
HIV infected children, remains uncertain. 
CMV disease in paediatric settings covers a spectrum of different disease 
entities for which the diagnostic modalities are different. The latter half of this 
chapter will review some of the local issues regarding the diagnosis of CMV 
disease in various paediatric clinical scenarios and examine the value of 
diagnostic tools in each of the scenarios. 
Congenital CMV infection 
Firstly in infants that are less than three weeks of age, it would be useful to 
identify CMV infection as this constitutes the diagnosis of Congenital CMV 
infection and these children would be managed differently. The presence of 
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circulating maternal antibody renders the use of CMV IgG fairly limited. CMV 
IgM is known to produce false positive results and should be interpreted with 
caution. The diagnostic assay of choice for congenital CMV infection is the 
detection CMV in the urine of the newbom by culture or PCR. CMV viruria is 
not only the most sensitive marker of congenital infection, but also suggested 
by Arav-Boger and Pass(5) as the gold standards for which monitoring of 
treatment can be based. In the majority of symptomatic congenital CMV 
infections, the viral burden in the urine is high and as a result, culture of the 
virus is the preferred method as sensitivity is not usually an issue. In our 
scenario the majority of infants are brought to the clinician's attention only 
after the first three weeks with signs and symptoms that may suggest 
congenital infection eg, hepatosplenomegaly, microcephaly, jaundice, 
intracerebral calcification, failure to thrive and skin manifestations. In these 
situations, congenital infection can not be confirmed as the detection of CMV 
does not necessarily represent infection prior to birth. In order to manage 
these infants not only should CMV infection be confirmed but also CMV 
disease. Currently in many European countries foetal cord blood is collected 
by means of dried blood spot routinely performed after birth, and this 
contributes greatly to the monitoring and diagnosis of congenital infections, 
especially CMV(6). Collection of foetal blood at the time of birth is gaining 
popularity and may replace detection of CMV viruria as means of diagnosing 
CMV infection. This would be an interesting research area that warrants 
further study of viability. Currently there is no data available on the 
prevalence of congenital CMV in this country. The only published African 
study was done in Gambia by Kaye et al. This study showed that congenital 
infection was low (3,9%) However, this is a region of low HIV prevalence. 
The congenital infection may be higher in areas of high HIV prevalence as 
HIV infected women are more likely to have recurrent CMV infection and 
pass it onto the foetus. 
Postnatally acquired CMV disease 
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Currently the diagnosis and management of postnatally acquired CMV 
disease in children depends on the nature of their clinical problem and the 
relative resources available to the attending paediatrician. For transplant 
recipients, the approach of prophylaxtic or pre-emptive treatment is used, 
while in H IV infected patients end organ disease is only sought when there is 
presence of symptoms. Antiviral therapy with ganciclovir (GCV) is instituted 
when end organ disease is confinned in an HIV infected infant. The two 
approaches will be discussed separately. 
The post transplant population has been well studied and a lot of the 
knowledge regarding CMV has been derived from prospective monitOring of 
these patients. The major difficulty with extrapolations from adult data is that 
children in South Africa are at a higher risk of developing CMV infection due 
to the high childhood CMV infection rate in this country. As a result, at Red 
Cross Children'S Hospital all post transplant children at risk of CMV infection 
are put on prophylactic ganciclovir and are monitored for an increase in CMV 
activity. CMV pp65 antigenaemia assay is used in older children and children 
that are at a lower risk of CMV disease. CMWL is used to monitor younger 
children and ill patients. According to the recommendation of International 
Herpes Management Forum (IHMF) the best type of sample for monitoring 
CMV DNAemia is whole blood as this is the most sensitive and reproducible 
sample type(40). The cut-off level of significant CMV activity in children 
remains undetennined as most of the studies involving children are small and 
the lack of standardisation makes comparison of data from various studies 
very difficult. Children with probable CMV disease are closely watched and 
the rate of increase of CMV viral load is the most accurate measure of CMV 
end organ disease in these children(40). Use of prophylactic ganciclovir and 
monitoring of CMV VL is costly. The use of diagnOSis and management of 
CMV in this group of patients partly reflects the resources that are available 
to these patients. 
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At Red Cross Children's hospital, HIV infected infants and children are 
managed quite differently to the above approach. As serial monitoring of 
CMV is not possible with these children, a tool to diagnose CMV end organ 
disease at clinical presentation is required before appropriate 
pharmacological intervention can be instituted. Currently a combination of 
CMV DNAemia (by qualitative PCR) and detection of CMV at the end organ 
by PCR, histology or viral culture are used to diagnose CMV disease. The 
commonest presentation of CMV disease in this population is pneumonia in 
infants of 2-5 months. Due to the high mortality rate and poor outcome of this 
clinical presentation, HIV infected infants in ICU are routinely started on IV 
ganciclovir and this is only discontinued if the initial CMV DNAemia is absent. 
Infants that are less ill or do not meet the requirements for ICU admission, 
need to have CMV DNAemia (by qualitative PCR) as well as CMV cultured 
from the respiratory tract before ganciclovir is given. This approach in 
severely ill ICU patients may lead to overtreatment with ganciclovir as CMV 
DNAemia is quite a common occurrence in HIV infected infants. In the less ill 
non-ICU infants this approach may lead to both overtreatment and 
undertreatment. CMV is shed in the respiratory tract of most CMV infected 
infants and culturing of virus in these infants does not conclusively prove that 
CMV is the causative agent for the respiratory distress. There is no data 
comparing CMV culture and histology in this group of infants and it is very 
likely that both methods are fairly insensitive in diagnosing clinical CMV 
pneumonia. Similar problems are encountered in other CMV EOD such as 
GIT disease, CNS disease, retinitis and systemic CMV disease. On the 
whole, outcome of suppressive therapy after clinical presentation of CMV 
disease is poor compared to outcomes of prophylactic or pre-emptive 
therapy(48). Nonetheless a cost effective and practical approach to these 
HIV infected children currently used at Red Cross Children's hospital would 
save many lives. 
Clinical management of CMV disease 
17 
International recommendations advise the treatment of paediatric CMV 
disease be conducted in two phases of pharmacological therapy: the 
induction phase followed by maintenance phase of therapy(36). The drug of 
choice for induction therapy is intravenous (IV) ganciclovir (5mglkg/dose 
twice daily administered intravenously over 1-2 hours) for 14-21 days. This is 
followed by maintenance therapy which may be life long. Due to financial 
constraints, maintenance therapy is not currently offered for HIV infected 
children with diagnosed CMV EOD at Red Cross Children'S Hospital. 
Currently 2 weeks of intravenous ganciclovir for a 4 kg infant will cost 
approximately R 10,000, not including the cost of hospitalization and 
administration of the drug. The long-term use of IV or oral ganciclovir has not 
been considered feasible due to cost, practicality, poor bioavailability, toxiCity 
and frequent dosing requirements. The risk of recurrent CMV disease 
following ARV induced immune reconstitution and discontinuation of 
gancidovir treatment has not been studied although anecdotal reports from 
Red Cross Hospital of CMV related deaths occurring after commencement of 
HAART suggest that this may be a Significant problem. 
Research needs and purpose of this MMed 
Currently in the field of paediatric CMV disease the following areas need to 
be addressed as a matter of urgency: 
1. The diagnostic value of qualitative CMV PCR and quantitative CMV 
PCR on whole blood samples for distinguishing CMV disease from 
infection 
2. The diagnostic value of Shell Vial culture on respiratory samples for 
CMV infection and CMV pneumonia. 
3. Adequate period of ganciclovir maintenance therapy following 
induction therapy 
4. An alternative to IV ganciclovir, as treatment of choice 
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5. Affordable monitoring tests for CMV activity (including possible 
congenital infection) in all HIV infected infants. 
6. An evidence based, practical, and affordable approach to HIV infected 
infants with severe pneumonia 
This study aims to address the current gap in our knowledge on the 
prevalence of CMV DNAemia in both asymptomatic HIV exposed infants and 
HIV infected infants with severe pneumonia. Without such data the meaning 
of this marker is unknown in this context. Further, there is a need to 
investigate an alternative good marker of CMV disease. Overwhelming CMV 
DNaemia has proven to be the only marker that independently predicts CMV 
disease across the various clinical scenarios. With the lack of better 
diagnostic modalities and serial monitoring of these patients, developing a 
reasonable cut-off of quantitative CMV PCR to predict CMV disease is crucial 
to improve the diagnosis of these disease entities. 
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Chapter 2 Material and methods 
Study design and study population 
This is a descriptive study designed to examine the prevalence and level of 
CMV DNAemia in whole blood samples from infants in Western Cape. Two 
groups of patients were examined: 
1) Asymptomatic H IV exposed infants tested for H IV as part of South 
African national Prevention of Mother to Child Transmission (PMTCT) 
program. 
2) Infants and young children admitted to Red Cross Children's 
Hospital with severe pneumonia. 
For the asymptomatic infants, random samples were selected from blood 
samples sent to the diagnostic virology laboratory at Groote Schuur Hospital 
for HIV PCR testing between April 2007 and September 2007. Infants who 
were hospitalized, had pneumonia or had failure to thrive as part of clinical 
information were excluded from this study group. This group represents the 
H IV exposed but asymptomatic component of the study. In total 328 samples 
were selected and 45 samples were excluded due to incompatible clinical 
status. Mothers were counseled not to breastfeed their infants in this study 
groups and formula feed was supplied to those unable to afford it. Whether 
the infants were actually breastfed could not be determined from the 
information available. 
The infants and children in the pneumonia group were taken from a 
prospective cohort recruited for a separate Pneumocystis Jerovecii 
Pneumonia (PCP) study based at Red Cross Hospital. The 
inclusion/exclusion criteria for the PCP study were as follows: 
Inclusion criteria for PCP/CMV study 
1. Severe Pneumonia: tachypnoea, recessions, 02 saturations < 90% in 
room air 
2. Suspected PCP: Severe pneumonia with one or more of the following: 
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• HIV suspected, HIV exposed or HIV infected children 
• ICU admission, Fi02>60% or Head Box 02 
• Malnourished or immunocompromised child e.g. 
chemotherapy, transplant recipient etc 
• Bilateral pulmonary infiltrates on CXR 
• Not responding to or deteriorating despite 48 hours of first line 
antibiotics and appropriate medical treatment 
• Air leaks ie pneumothorax Ipneumomediastinum (excluding 
empyema) 
Exclusion criteria 
1. No consent obtainable 
2. On PCP treatment (Co-trimoxazole) > 7 days 
At the time of this data analysis the study has yet to be completed and only 
the first 100 enrolled subjects have been included. This cohort represented 
the clinically ill group of the study. Five patients were further excluded 
because no blood samples were sent to the laboratory for CMV studies. In 
addition, for the pneumonia cohort, results of other investigations regarding 
CMV were also collected where testing had been done. They included Shell 
Vial culture on respiratory specimens and post mortem histology reports. 
CMV qualitative and quantitative (CMV VL) PCR were performed to 
determine the prevalence and level of CMV DNAemia respectively for both 
study groups. Detailed methodologies of these assays as well as DNA 
extraction method are described below. To determine the positive predictive 
value of the CMV DNAemia for identifying infants with CMV EOD, a sub-
group of infants from the severe pneumonia group were categorized as "CMV 
related pneumonia" on the basis that they fitted the following case definition: 
- Clinical and radiological parameters compatible with interstitial 
pneumonia on admission 
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- CMV infection confinned by qualitative PCR on whole blood 
- Detection of CMV in the lower respiratory tract either by CMV Shell 
Vial culture on bronchoalveolar lavage (BAL)lInduced sputum (IS) 
samples or by histology on a post mortem lung specimen. 
DNA extraction 
Extraction of nucleic acid was perfonned on the automated Roche MagNA 
Pure instrument using the whole blood protocol (MagNA Pure LC DNA 
Isolation kit I Roche Diagnostics, GmbH Mannheim Gennany) on 100 JJI of 
whole blood. The choice of whole blood over plasma and peripheral blood 
mononuclear cells was based on both practicality and sensitivity. DNA was 
eluted into 100 JJI of elution buffer from which both HIV and CMV PCR were 
perfonned. Negative controls were used with each extraction to monitor for 
possible contamination during the extraction process. 
HIV PCR 
Following DNA extraction, infants from both study groups were tested for HIV 
by means of PCR (Amplicor HIV-1 DNA test version 1.5, Roche Diagnostics, 
GmbH Mannheim Gennany) as part of routine investigations. Other than the 
use of MagNA Pure DNA extraction instead of manual DNA extraction, the 
assay was perfonned according to procedure stipulated in the kit insert. 
In house CMV PCR 
Screening for CMV viraemia was perfonned on all samples by qualitative 
nested PCR targeting the Immediate Early (IE) region. The outer primers 
were design by Dr Heidi Smuts to increase the sensitivity and specificity of a 
Single reaction PCR previously described by Ishigaki et al(25) For the outer 
reaction 10J.t1 of extracted DNA was added to 40J.t1 of mastennix consisting of 
1.5mM MgCI2, 200J.tM of each DNTP, 50rnM KCI, 10rnM Tris-HCI, 1.5U of 
Taq polymerase (Super-Thenn, JMR Holdings, Kent United Kingdom) and 20 
pmol of each outer primer. The outer primer sequences are as follows 
CMVs2 5'- GAG GCT A IT GTA GCC TAC ACT ITG G- 3' and CMVas2 5'-
CTC TAT CTC AGA CAC TGG CTC AGA C- 3'. PCR was perfonned on an 
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Applied Biosystems Geneamp 9700 thermal cycler with the following cycling 
conditions: 94°C for 2 minutes, 35 cycles of 94°C for 20 sec, 58°C for 30 sec, 
72°C for 45 sec and extension at 72°C for 7 minutes. 2J.l1 of outer PCR 
product was transferred into the nested reaction with 48J.l1 of mastermix 
containing 1.5mM MgCI2, 200J.lM of each DNTP, 50mM KCI, 10mM Tris-HCI, 
1.5U of Taq polymerase and 50 pmol of each inner primer. The sequences of 
inner primers were as follows: CMVs1 5'- CCA CCC GTG GTG CCA GCT 
CC - 3' and CMVas1 5'- CCC GCT CCT CCT GAG CAC CC - 3' (25). The 
cycling conditions for the nested reaction were 94°C for 2 minutes, 35 cycles 
of 94°C for 20 sec, 60°C for 30 sec, 72°C for 45 sec and extension at 72°C 
for 7 minutes. Detection of the PCR product was done by agarose gel 
electrophoresis and visualised under UV illumination with Ethidium Bromide. 
The PCR product size is 160 base pairs. Molecular marker VI (Roche 
Diagnostics, GmbH Mannheim Germany) was used to verify the size of the 
product. The analytic sensitivity of the nested PCR was not determined, but 
results from past external quality assurance panels suggest the nested CMV 
PCR has an analytical sensitivity of approximately 50 genome copies/ml 
sample input (data not shown). 
Quantitative CMV PCR 
Quantitative CMV PCR (Artus RealArt LC CMV PCR, Qiagen GmbH Hilden 
Germany), or CMV viral load (CMV VL), was performed on samples that 
were identified as positive by nested PCR in order to determine the level of 
viraemia. The assay was performed on the LightCycler 1.5 instrument 
(Roche Diagnostics, GmbH Mannheim Germany) according to the 
manufacturer's instructions. The analytical sensitivity of the quantitative 
assay is 541 genome copieslml using our extraction procedure (namely 
1001J1 sample extracted and eluted into 1001J1). The quantitative result is 
dependent on input volume and the following formula is used to adjust 
quantitative result according to input volume. 
Result (copies/ull X elution volume (ul) 
Result (copies/ml) = Sample input volume (ml) 
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Negative controls and strict unidirectional workflow within the designated 
PCR areas were used to prevent contamination of all PCR perfonned. All 
tests were subjected to the routine quality assurance measures implemented 
by our ISO 15189 accredited laboratory during the course of the study. 
Statistical analysis 
Statistical analysis was perfonned using statistical software StataSE version 
10. Shapiro-Wilk test for normality was perfonned. T test and Wilcoxon rank-
sum test were perfonned to establish statistical significance between two 
normal and non-nonnal distributed sample groups respectively. Odds ratios 
with 95% CI were calculated using logistic regression. Receiver Operator 
Characteristics (ROC) curve analysis was perfonned to determine a CMV 
viral load cut-off that would best predict CMV pneumonia when compared to 
our case definition. 
Ethics approval 
Ethics approval was granted by the ethics review board of University of Cape 
Town/Groote Schuur Hospital and Red Cross hospital for both the 
asymptomatic and severe pneumonia components of the study. 
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Chapter 3 Results 
CMV DNAemia in HIV-exposed asymptomatic infants: 
Of 283 HIV exposed, asymptomatic infants (characteristics of this study 
group are listed in Table 1a), 191 were HIV PCR negative and 92 were HIV 
PCR positive. The prevalence of CMV DNAemia was significantly higher in 
HIV-infected infants (p<0.001) than in HIV-uninfected infants: 41% of the 
HIV infected and 17% ofthe HIV uninfected infants had CMV DNA detectable 
in their blood (OR 3.36, Std err 0.96, 95%CI 1.93-5.90) by nested in house 
PCR. 
It was not possible to compare the prevalence of CMV DNAemia in HIV 
infected and uninfected infants under 2 months due to the small number of 
HIV infected infants in this age group, but 11% of HIV uninfected infants aged 
two months or less was found to have CMV DNAemia. This relatively low 
prevalence increased to around of 20% of HIV uninfected and 40% of HIV 
infected infants among infants older than two months. The proportion of 
infants with DNAemia remained fairly constant for the rest of the first year of 
life for both HIV positive and HIV negative infants (Figure 2). 
CMV viral loads (CMV VL) were perfonned among asymptomatic infants with 
CMV DNAemia. (Table 1c) Despite the increased prevalence of CMV 
viraemia in HIV infected infants, the mean CMVVL in the HIV positive infants 
(Mean=3.59 ± 0.98 log genome/ml) was only marginally higher than that in 
HIV negative infants (Mean=3.31± 0.86 log genome/ml). The difference did 
not reach any statistical significance (p=0.1). 
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Table la. A summary deSCllpllOO of the asymptomatic study group 
characteristics of the asymptoma\Jc PMTCT study group 
• 0=283 
• Median age 3 1 months (range 3 days - 12 months) 
• Clinically well Hospitalised IOfants excluded from the study group 
• HIV exposed - participants of PMTCT program 
• Sourced from a variety of local cliniCS throughout Westeln Cape 
• Counseled to avoid breastfeedlng as part of PMTCT and formula feed 
may be provided for some of the climcs 
• HIV PCR positive 921283 (33%) 
Prevalence of CMV DNAemia by nested PCR 
80% 
~ ""' u '0% 
I. '" • • .. ,,% .-
1k ".. ",% .- ""' • 
• HIV r.egatlVe 
• Htv po$<lIve 
< '"' • • <, , , • , , .. 
age (months) 
Figure 2 CMV Viraemia in HIVexposed asymptomatic Infants by age CMV 
DNA was detectlble 10 the blood of asymptomatic Infants from a very young 
age, rapidly reaching a steady rate of 20% for HIV negative IOfants and 40% 
fOf HIV POSitive IOfants. Age <2 months and 5 months categories of HI V 
posit ive Infant may be anomalies due to a small sample size 
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CMV DNAemia in infants with severe pneumonia: 
Of the 95 infants (characteristics of this study group are listed in table 1 b) in 
the severe pneumonia study group 30 were HIV PCR negative and 65 were 
HIV PCR positive. The median age (3.5 months) of children in this cohort 
was slightly older compared to that of the asymptomatic group (3.1 months), 
but the majority of patients were under 12 months of age. As was observed i1 
the asymptomatic component of the study, CMV DNAemia was significantly 
more common in HIV infected infants (OR 4.18, Std err 1.95, 95%CI 1.68-
10.44) (Table 1C). The proportion of children with CMV DNAemia in the HIV 
infected subset was 71 %, almost twice that of the HIV uninfected at 37%. 
The size of the group was too small to look at the prevalence of CMV 
DNAemia by age categories and HIV status. Instead, the proportion of infants 
with CMV DNAemia among age categories, irrespective of HIV status, was 
assessed in Figure 3. Among infants with pneumonia, 41 % of age two 
months or less had detectable CMV DNA in their blood. The prevalence of 
CMV DNAemia increased to 89% in infants of two months and remained 
above 50% for the rest of the first year of life. Older children with severe 
pneumonia had a slightly diminished prevalence of CMV viraemia at 44%. 
Breast milk is the commonest source of postnatal CMV infection. Using the 
breastfeeding history collected from children with severe pneumonia, we 
found breastfed children were at least 5 times more likely to be DNAemic for 
CMV (OR 5.39, Std error 2.86,95% CI1.9-15.2), but only marginally more 
likely to be HIV infected (OR 1.20, Std error 0.66, 95% CI 0.4-3.5). Table 3 
illustrates the significant difference in the prevalence of CMV DNAemia 
between breastfed and non-breastfed children. 
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Table 1 b. A summary description of the severe pneumonia study group. More 
than one possible causative agent was isolated from many of the patients in 
this study group. 
characteristics of the severe pneumonia study group 
• n = 95 
• Median age 3.5 months (range 19 days - 98 months) 
• Patients recruited from various wards in Red Cross Children's 
Hospital, include the intensive care unit. 
• Clinically ill children with pneumonia of various aetiologies: 
o PJP 16/95 
o CMV28195 
o Tuberculosis 7/95 
o Bacterial pneumonia 26/95 
o Other respiratory viruses 25/95 
• 36/96 (38%) participants of PMTCT program 
• HIV PCR positive 65/95 (68%) 
Table 1c. CMV viraemia rates by clinical status and HIV status 
Asymptomatic Severe pneumonia 
HIV HIV Total HIV HIV Total 





~edian age ± IQR 
month) 3±0.9 4±2.9 3.1±2.6 3.5±5.5 3.5±2 3.5±4 
CMVPCRPos 
kn, %) 
33(17%) 38{41%) 71(25%) 11(37%) 46(71%) 57(60%) 
28 
Prevalence of CMV DNAemia in children with severe 
pneumonia 
''''' ,-----r-----... .,.. 
" . .,. 
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'" ." age group Imonth.1 
Figure 3 CMV DNAemia In chIldren with severe pneumonia bV age CMV 
DNA was detected 10 the blood of Infants who had severe pneumoma from 
very early In life The number In each group IS 100 smail 10 further subdIvide 
age group by HIV status 
Table 3 Comparison between breastfed and non-breaslfcd children wl1h 
severe pneumom3 • p<0,01 
Breastfed " HIV pos HtV % CMVpos CMV% 
eo 35 21 60% 14 -- 40%' 
. 32 --yeo 45 71 % 34 76%' 
'-unknown " " 73% 8 53% -
" 
CMV vira l load in children with severe pneu monia 
CMV VIral loads were perfOfmed on all CMV ~lraemlC in fants The a~erage 
CMV VL m HIV mfected infants with pneumonia al109 4 3 was signi ficantly 
hlQher than m HIV-unmfected mfants With pneumonia al1093 4 (p=0.03) It 
was also slgllIficantly higher than for asymp!omatlc HIV Infected Infants at 109 
36 (p<O 01). and asymptomatic un-infected infants al 109 3 3 (p<O 01) 
(Table Id. Figure 4 ) 
Table ld CMV ~Iral load of all CMV PCR posltl~e sublects by cllllIcal and 
HIV status. The CMV VL of asymptcmatlc Infants (regardless of HIV status) 
and HIV unlnfected mfants With pneumonia were nOI significantly different. 
The CMV waemlCllll HtV ,nfected 'n fants, hQW'e~e" was significantly higher 
than all three ottief calegones Ip<0.05) 
'-'SO 
ml) 
WlilQR edlan eM 
Log copies! ml) 
Asymptomallc 
CMV PCR po5lllVf1 
HIV HIV Tolal 
ulunfec;ted infected (n"71) 
(n=33) (n=38) 
3 3tO 9 3.6il 3 510 9 
3 21t 3 3511 3311 I 
Se~ere Pneomoflla 
CMV PCR posillwe 
HIV HIV Total 
unlnfected infe<;ted (n=57) 
(n"" 1 (n:.46) 
~ -
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FIgure 4. CMV VL of CMV peR posltlve Infants by cliOical and HIV status 
The CMV viral toad In HIV negative mfanls with pneumonia was Similar to 
thaI of Ihe healthy Infants This could be conSidered the background level of 
CMV viraemia 10 the CMV Infected Infants 01 this age In contrast , CMV Viral 
loads were sIgnlflcanlly higher In HIV Infected InfanlS with pneumOnia It IS in 
Ihl5 group Ihal CMV is likely to playa role In Ihe pathogenesIs of HIV and/or 
CMVdlsease 
rhe mlants In the severe pneumonia group were found to have a range of 
causes for their pneumonia, Includmg other viral infec!ions (25195), bacterial 
causes (26J95) and PCP (16195). A subset of 21 infants wl'h pneumonia and 
CMV infection was selected according to our case definition to represent 
mfants with probable CMV-related pneumonia Clinical parameters of these 
patients are lis ted In table 4 The mean age of the infants with probabte CMV 
assOCiated pneumonia IS 3.9 months Of the 21 infants With probable CMV 
assocl8ted pneumonia: 17 were HIV exposed, 17 were HIV infected, 16 were 
known to be breastfed, 7 were CO-Infected With PCP and 4 had another 
respira tory virus cultured from the respiratory tract durlnglhe hospitalisation 
The mean CMV viral load of infants who filled our case definition 01 CMV 
related pneumonia (4 58±0 95 log copies/ml) was significantly higher than 
hospitalised children wilh non-CMV associated pneumonia (1 83± 2,09 log 
coples/ml, p<O.OI) (Figure 5) When only CMV DNAemic II1 lants were 
included for Ihe same comparison. the difference between Ihe two groups 
remall1s statistically significant (p=0.04, Figure 6) Our results also found that 
II1lanlS who fitted the case definition of CMV pneumonia were more likely to 
have been breaslled (OR 2.89 Sid Err 1.67 95%CI 0.93-8 99) and HlV 
intection increase the likelihood of CMV related pneumonia although less 
significantly (OR 2,21 , Sid Err I 21 95%CI 0,67-7 29) Among Ihe severe 
pneumonia cohort CMV is cultured from the NPA 0116121 patients with CMV 
associated pneumonia, significantly higher than Ihose without pneumonia 
(10n4. p<O,Ol) . 
We examine the sensillvity and specificity 01 CMV culture lor CMV infectJon 
uSing the DNAemia as a gold standard The two by two tables (Table 5 and 
Table 6) illustrale the performance of NPA and BAUIS viral culture when 
compared to CMV DNAemia. The sensillvlty, specificity, posilive predlcllve 
value (PPV), negative predictive value (NPV) of viral cullure from NPA were 
51 %, 91 %,88% and 59% respectively The viral culture fll1dings from BAUIS 
were similar to thai of NPA culture findings, namely 48%, 93%, 90% and 56% 
for sensiUvlty. specificity, PPV and NPV respeClively. 
To delermine the CMV viral load cut-off value best able to discnmll1ale 
between CMV pneumonia and non-CMV pneumonia. we performed ROC 
analysis (Figure 7) Assuming that all the cases analysed did have CMV 
pneumonia. We found that a CMV Vlfalload CUI-off value of 409 genome 
loglml was able 10 identify the CMV disease status correctly in 81% 01 the 
cases with a sensitivity 01 81 % and specificity of 78% The area under the 
curve is 0 8571 (95%CI 0.78-0 93), 
• • • I I • • 





Non-CMVassoclated CMV assooated 
Seville pneumorna 
Figure 5 Scalter plot of CMV VL by CMV association Each dot represents 
pallen!s in the severe pneumonia group CMV related pneumonia Is defined 
by 1 Clinical and radiologica l parameters compahble With interstitial 
pneumonia on admission 2 CMV Infection confirmed by qualitative peR on 
whole blood 3.Delectlon of CMV by ei ther CMV Shell Vial culture from 10000er 
respiratory tract (i e BAL or Induced sputum) or histology on an autopsy lung 
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CMV associated pneumonia Non-CMV associated pneumonia 
Figure 6 Bo)( and whisker graph comparing the level of CMV VIraemia 
among CMV ONAemic children with either CMV associated pneumonia Of 
non-CMV associated pneumOnia, 25-75 quartlles, the range and median of 
each group are represented by the bOle. whisker, and hOfllonlal hne 
respectively 
Table 5 Performance of VIral cul ture from NPA Of the 95 children from the 
&Cvc ro pnc\.!mQnliJ !jludy. l1J!1uitlj for NPfI cyt!uro gnd CMV peR were both 
a .... allable for 76 children 
DNaemia ONAemia I Iota! 
Posilive I Negahve 
-
NPA Culture POSItive 22 3 25 
NPA culture Negative 21 30 51 
total 43 33 76 
" 
Table 6 Performance of culture from the lower respiralory tract (BAL and IS! 
Of the 95 children from the severe pneumonia study. results for culture from 
the lower re,plratory tracl and CMV PCR were bo1h available for 69 d1i1dren. 
DNaemia DNAemia total 
Positive Negallve 
-
BAUIS Culture Pas Illve 19 2 21 
BALlIS culture Nega '.0 21 27 48 
total 40 29 69 
~ 
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Fi9ure 7 The ROC analySIS graph was used to asses the utility of CMV Vl In 
predlctln9 CMV disease A cut-off of 4 09 log copteslml was able to best 
separate the infants With probable CMV pneumonia from those Without. 
Table 4: Table of clinical info of CMV pneumonia children 
Age sex HIV Breastfed CD4 HIVVL log RR Sa02 PJP CMV culture Other Viral CMWL CMWL 
(months) count culture log 
IS/SAL NPA 
2.70 f Pos Unknown 15 NO 50 61 n pos neg neg 177350 5.25 
4.60 f Pos Unknown 76 >6.7 50 76 n pos neg Parainfluenza 3 24255 4.38 
3.80 f Pos No 40 NO 80 84 n pos pos neg 967900 5.99 
2.17 m Pos Yes 291 >6.7 80 66 n pos NO neg 504220 5.70 
2.80 f Pos Yes 629 >6.7 50 79 Y pos pos neg 14298 4.16 
1.23 m Pos Yes 2793 >6.7 50 n pos pos neg 51200 4.71 
2.23 f Pos Unknown 135 5.99 60 90 Y pos pos neg 14165 4.15 
2.70 f Pos Yes 488 >6.7 93 82 n pos pos neg 2680 3.43 
3.20 m Pos Yes NO 6.48 68 n pos pos RSV 152800 5.18 
5.37 m Neg Yes NO NO 62 81 Y pos pos neg 42990 4.63 
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Age sex HIV Breastfed CD4 HIVVL log RR Sa02 PJP CMV culture Other Viral CMWL CMWL 
(months) count culture log 
IS/BAL NPA 
3.63 f Pos Yes 296 >6.7 40 89 Y pos pos neg 176100 5.25 
2.97 f Pos Yes 157 NO 100 67 Y pos pos neg 27800 4.44 
1.93 f Pos Yes NO NO 90 83 Y NO* neg neg 365850 5.56 
3.27 f Pos Yes 526 NO 75 60 n pos pos RSV 3281 3.52 
3.33 f Pos Yes 934 >6.7 60 56 n pos pos neg 1959000 6.29 
2.97 f Neg Yes NO NO 60 89 n pos pos neg 470 2.67 
6.80 m Pos Yes 268 NO 50 86 n pos pos Parainfluenza 2 27015 4.43 
3.80 f Neg Yes NO NO 70 n pos pos neg 36500 4.56 
10.03 m Pos Yes 911 NO 64 88 n pos pos neg 761 2.88 
6.50 f Neg Yes NO NO 50 n pos pos neg 68100 4.83 
6.80 f Pos No 309 >6.7 70 77 Y Neg* neg neg 12340 4.09 
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IS - induced sputum 
NPA - Nasopharyngeal aspirate 
BAL - Broncho-alveolar lavage 
ND-Notdone 
* CMV pneumonia confirmed by post mortem histology 
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Chapter 4 Discussion 
CMV DNAemia in asymptomatic children 
Although clinical and laboratory observations suggest that CMV infection in 
Africa occurs at a very early age, it is very difficult to establish the exact 
epidemiology and prevalence of CMV infection in this early age group. The 
main tool used to determine seroprevalence, namely CMV IgG, cannot be 
used in young infants due to the ubiquitous presence of maternal antibody. In 
order to examine the age at which most of African children become infected 
with CMV, direct techniques such as CMV viral culture or CMV PCR will need 
to be performed on infants serially. Thus only a prospective study capturing 
the vertical CMV transmission in mother-child pairs, followed closely 
throughout the first few months of life, would be able to demonstrate the 
prevalence of congenital CMV and rate of acquisition of postnatal CMV 
infection. This important data of CMV epidemiology was lacking for African 
infants until the recent Gambian study conducted by Kaye et al. A cohort of 
mother-newborn pairs was follow up for 12 months to look for the source and 
timing of childhood CMV infection in Gambia. Their results showed 
apprOXimately 75% of infants were infected by 6 months of age and 85% of 
infants were infected by one year. The cumUlative prevalence of CMV over 
time showed that the majority of infants were infected with CMV between 8 
and 16 weeks. The incubation period of CMV is 4-8 weeks and if we 
extrapolate the Gambian data, the time of infection would be in the first two 
months of life. The implication of this finding confirms the suspicion that 
perinatal infection of CMV, especially through breastfeeding, is an important 
route of transmission in Africa. According to UNAIOS statistics, the HIV 
prevalence in adults in Gambia is around 2.7% and HIV infected infants 
would have comprised a relatively small proportion of their study cohort. In a 
high HIV prevalence area like South Africa, the number of CMV infected 
infants may be higher as HIV infected mothers are likely to shed more CMV 
than healthy women. Thus more local research is required to determine the 
epidemiology of infantile CMV infection in our setting. 
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In this study we examined the prevalence of CMV viraemia in HIV exposed 
well infants in Western Cape where the HIV prevalence among women 
attending antenatal clinics is 15.1 % (the 2006 South African National 
Antenatal survey by Department of Health). The infants that were selected in 
this component of the study were all from the local clinics where PMTCT was 
offered. This may represent a potential sampling bias as PMTCT was offered 
in areas which have better access to health care. This sampling method may 
not accurately reflect the findings in rural parts of South Africa. 
All infants were HIV exposed and had had their blood sampled for the 
purpose of determining their HIV status. Our results showed that overall 25% 
of HIV exposed asymptomatic infants had detectable CMV DNA in their 
peripheral blood. CMV viraemia was present at a very early age and was 
much more common in HIV infected infants (41 %) compared to HIV 
uninfected infants (17%). The high prevalence of CMV viraemia observed at 
the early age in our study population is in keeping with the recent finding by 
Kaye et a/ which indicated that natural CMV infection frequently occurs in 
early infancy in Africa. Classically the most significant route of transmission 
of CMV for the African newborn is through breastfeeding. In our 
asymptomatic study group, mothers of the study subjects were given formula 
feeds and advised not to breastfeed as part of the PMTCT program. Despite 
this, our results indicate that more than 10% of two month old H IV exposed 
infants had CMV viraemia. The CMV viraemia rate remained fairly constant 
at around 20% up to the age of 12 months. This early DNAemia up to 3 
months suggests that infection occurred during the early neonatal period, 
most likely during the childbirth process or subsequent close contact 
although the possibility that some may have acquired inection via 
breastfeeding cannot be excluded. Furthermore, detection of CMV in the 
urine is widely considered to be the most sensitive technique for diagnosing 
CMV infection as DNAemia is likely to be transient in most CMV infections. 
The DNAemia figures that we collected are likely to be an underestimate of 
the actual CMV prevalence in this group. Unfortunately due to the nature of 
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the study we were unable to examine the utility of DNAemia as a marker of 
CMV infection. 
In a study by Kovacs and colleagues(31), HIV infected infants, despite having 
similar CMV infection rates at birth, were significantly more likely to be 
infected by CMV at six months (as determined by CMV culture in the urine). 
This conclusion is supported by our DNAemia data where HIV infected 
infants were more than twice as likely to have CMV DNAemia than HIV 
uninfected infants (Table 1 a). A few factors might account for the high 
prevalence of CMV in HIV-infected infants. Firstly, the normal cell mediated 
immunity required to control CMV replication may be impaired in the HIV 
positive infants and as a result they may take longer to clear the CMV 
viraemia. Collectively this would influence the prevalence of viraemia. 
Secondly, the HIV positive infants represent the group where PMTCT has 
failed. The failure of PMTCT may be attributed to higher maternal HIV viral 
load, intermittent breastfeeding due to poor access to formula among other 
factors that could increase the risk of early CMV acquisition. Thirdly this may 
be a result of an increased incidence of congenital CMV infection which 
presents with persistent viraemia in the ensuing months following birth 
although whether maternal HIV infection increases congenital CMV infection 
remains controversial(16;37). 
Based on our findings, a practical implication is that the role of CMV PCR 
needs to be re-examined in the current clinical setting. The high prevalence 
of CMV DNAemia in an apparently well cohort indicates that this very 
sensitive assay can detect presence of CMV that has not resulted in clinical 
disease. CMV PCR is currently being used as a guide to manage infants with 
suspected CMV disease at Red Cross Hospital but it has a very low positive 
predictive value for CMV disease. While its negative predictive value is good, 
a positive result needs to be interpreted in combination with other clinical or 
laboratory parameters before CMV EOD can be diagnosed. 
In CMV viraemic infants, the level of CMV DNAemia was further defined by 
quantitative CMV PCR. Comparing the level of DNAemia between the HIV 
infected and HIV uninfected asymptomatic infants, the mean CMV viral loads 
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were similar, 3.59 log copies/ml for the HIV infected and 3.3110g copieslml for 
the HIV uninfected. Predictably, the difference did not reach any statistical 
significance. As the level of viraemia is the best predictor of CMV disease, 
we expected infants without EOO to have similarly low levels of CMV viral 
load. The marginally higher viral load in HIV infected infants may be due to 
poorer immune control of CMV in the HIV infected infants, but the effect of 
the small study sample size may limit further interpretation of this 
comparison. Nonetheless, the CMV viral load in our asymptomatic group is a 
novel finding and would be useful in guiding the interpretation of viraemia 
level found in symptomatic infants. 
CMV DNAemia in children with severe pneumonia 
Most healthy infants who acquire CMV infection in the first year of life cope 
well with the infection and CMV disease in healthy immunocompetent infants 
is very uncommon. Infants who are immunocompromised due to prematurity, 
congenital immunodeficiencies or HIV infection are more likely to develop 
symptomatic infections. They can either manifest as a glandular fever like 
systemic illness or end organ disease such as retinitis, pneumonia, colitis or 
CNS disease. 
When examining CMV prevalence data in infants with severe pneumonia, 
two distinct trends emerged. Firstly the CMV ONAemia was very common in 
the first year of life: 41 % of infants under the age of 2 months old were 
viraemic for HCMV, increasing to 89% by two months, and dropping to less 
than 50% by a year. This prevalence trend is consistent with the age at which 
infants present with CMV disease to Red Cross Children's Hospital, namely, 
in the 2 to 5 months age group. Primary CMV infection in African infant 
occurs commonly in the first two months of life. In HIV/CMV co-infected 
infants CMV pneumonia at 2-5 months of age may be a manifestation of 
persistent primary CMV infection. CMV related pneumonia has a high 
mortality in this age group and the lower prevalence seen in older children 
may reflect either infants that were infected later during infancy or a group of 
perinatally infected infants that had better control of CMV replication. A 
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prospective study is clearly required to investigate the relationship between 
primary CMV infection and CMV EOD. This may shed light on the reason 
why infants between 2-5 months are particulal1y susceptible to CMV disease. 
Secondly, as observed in the asymptomatic component of the study, HIV 
positive infants were more likely to have CMV viraemia. The overall high 
prevalence of CMV DNaemia (71%) in these ill infants may reflect the higher 
prevalence of HIV in this group. Compared to the asymptomatic groups (HIV 
prevalence 33%), the HIV prevalence of pneumonic children were twice as 
high (68%). 
Interestingly, the pneumonic infants were more than twice as likely to have 
CMV viraemia than healthy infants, regardless of their HIV status (37% vs 
17% in HIV negative infants, OR 2.77 [95%CI1.21-6.37] and 71% vs 41% in 
HIV infected infants, OR 3.44 [95%CI1.75--6.77]). Studies have shown that in 
immunocompromised individuals, CMV infection is a contributor of illness and 
disease progression(1;11;27;42). Williams and colleagues found, among 
infants with vertically acquired HIV, CMVand PCP co-infection was 
associated with a worse prognosis than PCP infection alone(52). Frenkel et 
at studied 38 HIV exposed infants prospectively and their findings suggested 
that 1) CMV infection plays an important role in H IV progression and 2) 
symptomatic CMV infection is associated with increased morbidity and 
mortality of these children(19). CMV is well known to have a detrimental 
effect in transplant patients (44). More recently, in a study by Limaye et al it 
was found that CMV reactivation plays an adverse role in critically ill 
immunocompetent patients as well (33). Further randomized control study 
looking at ganciclovir prophylaxis vs placebo in the critically ill 
immunocompetent patients are in the pipeline. Our data support the 
hypotheses that acute illness in general can result in reactivation of CMV. 
The difference in the proportion of patients with DNAemia between the HIV 
status-matched groups, 20% for HIV uninfected and 30% for HIV infected 
children, could represent the proportion of individuals with reactivation of 
43 
CMV during an acute illness. The role of ganciclovir prophylaxis should be 
similarly studied in critically ill immunocompromised infants. 
The influence of breastfeeding on prevalence of CMV DNAemia in 
pneumonia cases was examined. Our data confirmed that there was a higher 
prevalence of CMV DNAemia, much more than its effect on HIV 
transmission, among the breastfed children (table 3). Currently, many studies 
in developing countries have investigated the role of exclusive breastfeeding 
while giving HAART to either the mother or the infant. The concept of using 
HAART to prevent transmission of HIV from the mother to the child via 
breastfeeding(7;47) is attractive. However, these studies have shown that 
when the PMTCT fails in these circumstances, the outcomes are generally 
poor due to drug resistant virus in the infected infants. In most 
circumstances, the sub-therapeutic level of HAART in breast milk is unable to 
suppress the HIV viral replication in that compartment and the transmission 
of these selected strains of HIV results in the infant infected with drug 
resistant HIV de novo. Our study findings present another aspect which 
should be noted when the exclusive breastfeeding approach is taken. Current 
literature indicates that CMV DNAemia is a known contributor to HIV disease 
progression. The failure of PMTCT in the setting of breastfeeding will 
undoubtedly result in a high proportion of infants with early H IV and CMV 
dual infection which favours rapid HIV disease progression. This may in part 
explain some of the poor outcomes of cases where this PMTCT strategy has 
failed. 
When a new diagnostic assay becomes available, in addition to evaluating its 
utility, the performance of the existing assay can be Similarly examined. CMV 
DNAemia identifies infants with systemic CMV infection and this can be used 
as a gold standard for which the sensitivity and specificity of CMV culture 
could be assessed. The performance of shell vial culture performed on NPA 
and lower respiratory tract samples (BAL and induced sputum) was 
compared with CMV DNAemia in infants with pneumonia. 
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As CMV is commonly shed in the saliva among CMV infected infants, one 
would expect an NPA from an infant who had detectable CMV in the blood to 
be culture positive as well. Our data showed that culture of NPA was only 
able to detect 50% of CMV infections identified by DNAemia. Though culture 
of NPA samples detected 3 additional CMV infections in non-DNaemic 
infants, the overall sensitivity of the assay for CMV infection was poor. This 
low pick up rate could reflect poor sample quality, technical problems with 
CMV shell vial assay, or lack of viral shedding from the nasopharynx despite 
CMV infection. Further studies using CMV PCR on respiratory samples are 
underway to determine the exact sensitivity of the CMV culture in this 
context. Currently the low yield of CMV viral culture is considered a benefit as 
it is thought only a high level of viral shedding would be detected by this 
relatively insensitive method. However, there is no evidence that CMV 
pneumonia has any association with CMV shedding from the upper 
respiratory tract. CMV is frequently shed in the oropharynx by healthy 
individuals and thus culture of CMV from the upper respiratory tract is also 
likely to yield low specificity for CMV pneumonia. The combination of above 
factors suggests that CMV culture from NPA may be a fruitless laboratory 
investigation and the current clinical practice may need to be altered. 
The performance for culture from the lower respiratory tract at a glance looks 
similar to that from upper respiratory tract. Its current clinical use is to detect 
CMV pneumonia and a culture positive BAL or IS in conjunction with CMV 
DNAemia is considered diagnostic of CMV pneumonia in an infant with 
compatible clinical feature(3). This clinical testing strategy is biologically 
plausible. Systemic CMV activity plus isolation of CMV at the site of disease 
is a reasonable indicator for CMV pneumonia. However, the sensitivity of 
culture from the lower respiratory tract is a cause for concern and literature 
on the sensitivity of culture from BAL are divided(14;24;34;49). Further 
examination of the data revealed that the culture result of upper and lower 
respiratory tract had 91 % concordance. It is possible that the technique of 
viral culture may be an insensitive marker of CMV disease. Some studies 
have suggested that a proportion of CMV pneumonia is a result of 
immunopathology and therefore isolation of the organism may not represent 
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the full picture of CMV EOO at the lung(23). From the sampling perspective, 
retrieving a good sample from the lower respiratory tract is both labour and 
skill intensive. When all the above factors are taken into consideration, viral 
culture 'from BAL alone may not be sufficient to diagnose CMV pneumonia 
and an adiitional good laboratory marker of CMV EOO is still needed in this 
clinical context. 
While the presence of viraemia may support the diagnosis of CMV EOO in 
certain contexts(10). in infants it commonly reflects recent primary CMV 
infection(55) or subclinical CMV reactivation. It is therefore important to 
quantify the level of viraemia and compare to the level found in asymptomatiC 
infants. Despite the high prevalence of ONAemia found in the HIV uninfected 
infants with pneumonia, the mean CMV viral load (3.4 ± 0.9 log copieslml) 
was comparable to that seen in the asymptomatic infants (3.5 ± 0.9 log 
copieslml), and significantly lower than that in HIV infected infants with 
pneumonia (4.3 ± 1.2 log copieslml). This is not surprising as CMV is an 
uncommon cause of pneumonia in immunocompetent infants. The slightly 
higher CMV viral load seen in the HIV negative infants with pneumonia could 
reflect CMV reactivation in the face of another serious illness. The 
Significantly higher CMV VL seen in the HJV positive infants, on the other 
hand, suggests that this marker is able to distinguish between asymptomatic 
reactivation and CMV EOO. However. these results alone only suggest that 
Significant CMV ONAemia is more likely to be present in an HIV infected 
infants with pneumonia. Further, the range of CMV VL's for both 
asymptomatiC infants and infants with severe pneumonia were both broad, 
ranging from the absolute lower detection limit of around 2 log genome 
copies/ml to >6 log copies/mi. There was also significant overlap in the JQR 
between the HIV infected asymptomatic infants (3.6 ± 1 log copies/mJ) and its 
pneumonic counterpart (4.3 ± 1.2 log copies/mI). To determine whether CMV 
VL can accurately differentiate CMV EOO from CMV reactivation, more 
analyses need to be performed comparing infants with and without laboratory 
confirmed CMV EOO. 
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therefore infants with multiple pathogens should not be excluded from the 
analysis of CMV disease. 
We found that the infants with probable CMV related pneumonia had a 
significantly higher mean CMV viral load (4.56 log copies/ml) compared to 
the HIV uninfected infants with pneumonia (3.6 logs copies/ml) (p<O.01). This 
mean viral load was also significantly higher than in asymptomatic HIV 
positive infants (p<O.01) and asymptomatic HIV negative infants (p<O.01). In 
clinical practice, CMV PCR is often performed first to rule out CMV disease 
as this test has a high negative predictive value. We therefore analysed the 
data further by only comparing ONAemic infants with and without pneumonia 
(Figure 6). The level of ONAemia was still significantly higher in the ONAemic 
infants with pneumonia group. This confirms findings from other clinical 
settings that the quantitative CMV viral load has a role in predicting CMV 
disease. However, the infants with high CMV VL in the non-CMV pneumonia 
are a cause for concern. These infants could have CMV related disease in 
another organ. Unlike in adults, CMV end organ disease such as retinitis and 
oesophagitis in infants does not present with specific complaint. When these 
extra-pulmonary EOO present concurrently with pneumonia, the diagnosis 
may be missed. Thus regardless of whether CMV was cultured in the 
respiratory tract, presence of high level of CMV ONAemia should alert the 
clinician to the possibility of CMV EOO. 
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Determining a threshold DNAemia for CMV disease 
ROC curve analysis is a common tool used to evaluate and refine the 
performance of medical diagnostic assays. A data set with known true 
positive results (or results using a gold standard assay) is required for this 
analysis. Using individual values in the data set as the cut-off for the rest of 
the data set, a list of sensitivities and specificities can be generated for each 
value. This is plotted on a graph with y axis being sensitivity and x axis 
1minus specificity (1- specificity Le. false positive rate). From this list of 
sensitivities, one can determine the best cut-off that is able to predict most of 
the result correctly. Simply put, it is a tool to establish a cut-off that would 
maximize sensitivity and minimize false positivity. 
In the severe pneumonia component of this study, we used a set of clinical 
and laboratory criteria as the "gold standard" for diagnosing CMV-related 
pneumonia. The CMVVL was then measured for each of the infants in this 
cohort with the non-viraemic children's CMV VL set at zero log copies/ml 
whole blood. The ROC analysis performed from this data indicated that using 
a cut-off of 4.09 genome log we would be able to produce the best 
concordance rate with the gold standard, correctly identifying infants with 
CMV-related pneumonia in 81% of cases. 
Importantly. the result of ROC curve analysis would depend on the dataset 
collected. Just as the disease prevalence of the cohort would influence 
positive and negative predictive value of an assay, so would characteristics 
of the cohort examined influence the cut-off determined by the ROC analysis. 
Various different sets of CMV VL cut- offs have been established by previous 
studies done in various other clinical contexts. Some of the cut-offs were 
reviewed by Arav-Boger and Pass(4). Both Lilleri et al (32)and Cope et al 
(13) used CMVVL of >100,000 on whole blood as a cut-off to predict CMV 
disease in solid organ transplant recipient whereas Boppana (8) and 
colleagues found 10,000 genome equivalents/ml to be predictive of 
symptomatiC disease in congenitally and perinatally infected infants. In 
studies focusing on HIV infected individuals, Brantsaeter et al (10) found that 
a cut-off of 10,000 copies/ml yielded a positive predictive value of 100% 
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when compared to post mortem histological findings. Wiselka and 
colleague(53), on the other hand, found the cut-off of 100 copies/ml have the 
positive and negative predictive value of 44% and 82% respectively. 
It is very difficult to interpret these findings and extrapolate them to our 
paediatric setting for many reasons. Firstly there is no internationally 
standardized measurement of CMV genome. The findings of the above 
studies are all done using different methods. Without a denominator, these 
assays, many of which are in house, cannot be compared. Secondly the type 
of blood compartment (plasma, whole blood or peripheral blood leukocytes) 
tested was also different. The IHMF recommends whole blood as the ideal 
compartment for the measurement of CMV DNAemia due to its sensitivity 
and practicality. Perhaps future studies will heed this recommendation and 
use whole blood as the starting point of DNAemia estimate. Thirdly the 
targets of PCR and methodology of PCR were also not standardized. Finally, 
other environmental factors may influence the level of viraemia in different 
studies. Thus in order to establish a threshold for our local paediatric setting, 
we can only use local data to guide us. Nontheless, the cut-off determined in 
the study seems to be in line with the findings of others, namely that a cut-off 
between 4-5 logs copieslml whole blood is likely to be useful to predict CMV 
EOD. 
ROC curve analysis can also be used to estimate the overall performance of 
the assay by looking at the area under the curve (AUC). The AUC represents 
the assay performance at all cut-off values. The range is between 0.5 and 1. 
The closer the individual plots are to the y axis, the higher the AUC. The 
higher the AUC is, the better the assay performance. Our CMV VL had an 
AUC of 0.86 (95% CI 0.78-0.93) which shows in this clinical setting the assay 
has a fairly good diagnostic utility. 
Unfortunately without autopsy findings and prospective testing, our study was 
unable to truly delineate CMV related pneumonia from the rest. A prospective 
clinical study in which infants are routinely biopsied for CMV histology would 
be required to truly determine the sensitivity and specmcity of CMV viral load. 
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In the absence of such a study, we believe that CMV viral load may play an 
important role in guiding the clinician to better manage these infants. 
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Chapter 5 Conclusion 
In conclusion, we report the novel finding that asymptomatic CMV viraemia in 
HIV-exposed infants is common. Forty one percent of asymptomatic and 
71 % of ill infants with pneumonia were found to have CMV DNAemia. This 
high prevalence of DNAemia would negatively influence the PPV of 
qualitative CMV PCR for diagnosing CMV pneumonia. The presence of CMV 
DNA in the blood of ill infants does not discriminate between infection from 
disease and should be interpreted with caution. DNAemia, however, may still 
be a useful screening tool to identify HIV infected infants at risk of CMV 
disease or accelerated HIV progression and to exclude CMV disease as its 
NPVishigh. 
We further noted that CMV DNAemia was much more common in HIV 
infected infants than HIV-uninfected infants and acutely ill patients 
(represented by our severe pneumonia study group) were much more likely 
to have CMV DNAemia than their asymptomatic counterparts. This difference 
in prevalence may not translate into clinical Significance, as quantitative 
results indicate that only HIV infected infants with pneumonia had a 
significantly higher CMV viral load in the study groups examined. 
From infants with severe pneumonia, our data indicated that breastfeeding is 
a significantly associated with CMV DNAemia. Breastfeeding in HIV infected 
infants may thus represent a risk factor for CMV Infection and disease. 
The evaluation of existing viral culture techniques in infants with severe 
pneumonia showed that upper and lower respiratory tract samples yielded 
similar low NPV when compared to DNAemia. The role of CMV culture from 
respiratory tract in diagnosing CMV pneumonia would be better evaluated in 
a prospective study but viral culture of NPA is not helpful for detecting CMV 
pneumonia. 
Despite the significantly higher CMV viral load in infants with probable CMV 
pneumonia, we could not identify a cut-off that produced clear separation 
between those with CMV disease and those without. The cut-off of 4 log 
copieslml of whole blood was able to correctly identify 81% of infants with 
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suspected CMV pneumonia in our study. This is in line with the threshold 
found in other international studies. This would be a good starting point for 
which future clinical studies can assess the relationship between CMV end 
organ disease and CMV viraemia. 
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Comparison between CMV related pneumonia and non-CMV related 
pneumonia among children with severe pneumonia 
In Sun-Saharan Africa where CMV prevalence is high among children, HIV 
and pneumonia disease burdens are both high. 80% of HIV infected infants 
develop respiratory tract illness during their course of disease. HIV infected 
African infants admitted with severe pneumonia is associated with a case 
fatality rate of 20% to 34%; three- to six-times higher than children who are 
not infected with HIV(26). Although the aetiology of this severe pneumonia is 
polymicrobial, CMV has been found more frequently in HIV infected infants in 
studies examining cause of the severe pneumonia(12;22;27;54) and the 
outcomes of CMV pneumonia among HIV infected individuals are 
poor(41 ;50;51). This is in stark contrast of the pre-HMRT era of first world 
countries where CMV plays little role in the respiratory illness of HIV infected 
infants(21;54). Despite this significant health problem unique to developing 
countries, there are very few studies that address the diagnosis of CMV 
associated pneumonia. As a result clearly defined CMV pneumonia among 
HIV infected infants is under represented in the literature. 
To define the CMV DNA level associated with CMV disease, we chose to 
study infants with CMV related pneumonia, a common clinical manifestation 
of CMV disease in our setting. The parameters used in our case definition 
were largely based on criteria commonly used to define CMV pneumonia in 
adult HIV infection and transplant recipients (20;45). We deviated from the 
original definition in that we did not exclude individuals from whom another 
microbe had been isolated. The main reason for this was that many studies 
have shown that HIV infected infants are prone to respiratory tract infection 
caused by more than one pathogen, including bacteria, viruses and fungi. In 
each of these situations, CMV may play an important role in exacerbating the 
respiratory tract infection. In most cases of CMV infected children with severe 
pneumonia, there is an additional pathogen present. Previous autopsy 
stUdies have identified CMV as an important contributor to pathology and 
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